Vir Biotechnology Inc VIR

$10.57 +0.14 (1.34%)

Valuation

Market cap
1,788,613,000
Revenue TTM
$68,560,000
Net income TTM
$-437,990,000
PE ratio
0.00
Forward PE
—
Profit margin
-638.84%
Debt to equity
0.00

Trading

Volume
1,693,500
Avg volume
2,034,016
Day's range
$10.03 – $10.59
Shares out
169,216,000
Stochastic %K
49%
Beta
1.59
Analysts
Strong Sell
Price target
$21.00

Price

Company profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A a...

Show more

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 906 4324
Website
https://www.vir.bio
Address
1800 Owens Street, Suite 900, San Francisco, United States

Latest news

Stocktwits

wintogether Oct 25, 4:54 PM
$VIR Will they have any presentations at ESMO next year?
0 replies
Merlintrader Oct 22, 7:58 PM
$VIR Latest company news, Oct 21, 2026: Vir Biotechnology will host its Q3 call on November 4 at 4:30 p.m. ET. Vir Biotechnology ($VIR): HDV Readout Meets an Expanding Oncology Platform https://www.merlintrader.com/vir-biotechnology-stock-hub/ Chart (daily): price around 10.4, slightly below the 50-day moving average (about 10.7) and above the 200-day (about 9.4). Since September it has traded roughly between 10 and 12, with the upper trendline near 11.8-12. The rising trendline from the June lows now sits near 9.7. Not investment advice.
0 replies
JuliusCoolius Oct 22, 2:08 PM
$GILD $VIR @multrak fair points. I have no interest in rebutting your every point. If you think the company is scamming you then you should sell now. I come to biotech investing knowing that treatment discovery is a long and winding road. The majority of treatments fail to meet endpoints and companies need to decide if continuing is wise. I don’t expect every drug candidates to become blockbuster drugs. I believe companies need to be transparent but I don’t share your view that everything is bad.
1 replies
JuliusCoolius Oct 22, 1:15 PM
$VIR The type of news this company has released and the muted (read negative) stock market reaction frustrates even the most seasoned investor. In case you missed it, they got a fast track designation from the FDA for one of their drug candidates. They also signed a deal with Gilead, with millions up front, to identify and collaborate on three drug candidates using their new platform and drug discovery method. The Gilead deal is more significant than meets the eye, since it potentially assigns value to the platform and method rather than just the drugs themselves. It means other big companies could come and pay Vir for collaboration on candidates targeting different things, with Vir getting a small royalty cut. That potential licensing business would set Vir up as a major drug discovery powerhouse. Licensing revenue would be akin to recurring revenue in the software world, carrying a whole new risk profile and therefore higher multiple.
1 replies
Rubener Oct 22, 12:20 PM
$VIR Short Percent of Float: 9.12% Change from Previous Report: -23.80% (down from 19.66 million shares or 13.41% of the float on September 15, 2026
0 replies
investpapaya Oct 22, 11:14 AM
$KURA and also, $VIR may quietly become major winners in the oncology space.
0 replies
Dunnieboy1 Oct 22, 10:37 AM
$VIR strange to say but compared to most shares Vir is holding up well at the moment.
0 replies
multrak Oct 21, 8:37 PM
$VIR why what you see in stocktweets versus robinhood is different? especially for vir? I see 200k after hours volume here and not elsewhere.
0 replies